Tianyu Pharmaceutical approves key resolutions at 2024 AGM

Zhejiang Tianyu Pharmaceutical (SZSE:300702) announced the successful passage of all resolutions at its 2024 Annual General Meeting held on May 12, 2025. Key resolutions included the approval of the 2024 Board of Directors' and Supervisory Committee's work reports, the 2024 annual report and its summary, and the 2024 financial statement report. Shareholders also approved the proposed 2024 profit distribution plan and the re-appointment of the auditing firm for 2025. The meeting saw participation from 233 shareholders and authorized representatives, representing 224,606,584 shares, or 64.5464% of the company’s total shares. The approval of director and supervisor remuneration plans, as well as plans to conduct foreign exchange hedging, were also passed. The company's board has been authorized to handle matters related to issuing shares to specific targets under a simplified procedure.